

## ISR signs contract with Northway Biotech, CMO for Vaccin production

ISR is now partnering with Northway Biotech, Lithuania, a Contract Manufacturer Organization (CMO organization), to conduct the tech transfer of recombinant GMP production of SARS-CoV-2 spike protein to the Phase III vaccine study and after market approval.

*"We are already starting to prepare the production of vaccine for the next phase III study and for market entry. By engaging a CMO company with extensive experience in large-scale GMP production of recombinant proteins early, we ensure rapid introduction to the market."*, comments Ola Winqvist, CEO ISR.

ISR Immune System Regulation Holding AB (publ) is a pharmaceutical company that conducts research, development and is in phase II drug testing. The company develops its own candidates, renews indications for diseases where the immune system has a central role. Development takes place in the areas of HIV, Hepatitis B, immuno-oncology and vaccines.

**For further information, please contact:**

Ola Winqvist  
CEO, ISR Immune System Regulation Holding AB (publ)  
E-post: [ola.winqvist@israb.se](mailto:ola.winqvist@israb.se)  
Phone: +46 (0)70 5427939

**About ISR Immune System Regulation Holding AB (publ)**

*ISR is an innovation driven pharmaceutical development company within immunotherapy. The company focuses on clinical and preclinical research, with the goal to develop a broad-spectrum antiviral platform of immune regulating pharmaceuticals. Mangold is the company's Certified Adviser, and can be reached on phone +46 (0)8-463 80 00.*

[www.israb.se](http://www.israb.se)

*This information is subject to compulsory publication by Immune System Regulation Holding AB (publ) complying with EU's Market Abuse Regulation (MAR), and the Market Abuse Act*